Protective effects of cilostazol against cisplatin-induced hepatorenal toxicity in male mice
Research in Pharmaceutical Sciences · 2026-03 · 21 (2) · 227-235
DOI: 10.4103/rps.rps_199_24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Research in Pharmaceutical Sciences, online erschienen am 24.04.2026. Verfasst von Elham Hakimizadeh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Physiology-Pharmacology Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and purpose: Cisplatin (CPN) is a widely used and potent chemotherapy drug for cancer treatment. However, one of the major side effects of CPN is hepatorenal toxicity. Recently, cilostazol (CSZ), a type III phosphodiesterase inhibitor, has promising effects against liver and kidney toxicities. We assessed the effects of CSZ against CPN-induced hepatorenal toxicity (CIHR) in male mice. Experimental approach: Twenty-four male mice were randomly assigned as follows: control group (no treatment), CPN group (treated with 20 mg/kg CPN on day one of the experiment), and CPN + CSZ 3 and 15 groups (treated with CPN on day one of the experiment plus CSZ (3 and 15 mg/kg) orally for four days). Biochemical, oxidative, and histological investigations were conducted to evaluate the effectiveness of CSZ in protecting the liver and kidneys from CPN-induced damage. Findings/Results: The results showed that treatment with CSZ, especially at 15 mg/kg, significantly reduced the CPN-induced increase in serum concentrations of biochemical markers such as alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, blood urea nitrogen, and creatinine. Furthermore, CSZ treatment at 15 mg/kg also restored the hepatorenal oxidative stress factors, including superoxide dismutase, malondialdehyde, and glutathione peroxidase. Histological examination revealed a significant improvement in groups receiving CSZ (15 mg/kg) compared to the CPN-treated group, alongside biochemical and oxidative results. Conclusion and implications: The findings of this investigation point towards the potential of CSZ as a viable contender for subsequent exploration in the realm of devising efficacious therapeutic approaches for CIHR.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Physiology-Pharmacology Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
- Department of Radiology, Afzalipour Medicine School, Kerman University of Medical Sciences, Kerman, Iran.
- Research Center of Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran.
- Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
- Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Zitieren
APA
Hakimizadeh, E., Khajehasani, F., Amirteimoury, M., Kaeidi, A., Hassanshahi, J., & Fatemi, I. (2026). Protective effects of cilostazol against cisplatin-induced hepatorenal toxicity in male mice. Research in Pharmaceutical Sciences, 21(2), 227-235. https://doi.org/10.4103/rps.rps_199_24
Vancouver
Hakimizadeh E, Khajehasani F, Amirteimoury M, Kaeidi A, Hassanshahi J, Fatemi I. Protective effects of cilostazol against cisplatin-induced hepatorenal toxicity in male mice. Research in Pharmaceutical Sciences. 2026;21(2):227-235. doi:10.4103/rps.rps_199_24
BibTeX
@article{Hakimizadeh2026,
author = {Hakimizadeh, Elham and Khajehasani, Fatemeh and Amirteimoury, Morteza and Kaeidi, Ayat and Hassanshahi, Jalal and Fatemi, Iman},
title = {Protective effects of cilostazol against cisplatin-induced hepatorenal toxicity in male mice},
journal = {Research in Pharmaceutical Sciences},
year = {2026},
volume = {21},
number = {2},
pages = {227--235},
doi = {10.4103/rps.rps_199_24}
}
EUVIMED